Oculis Holding AG opened lower at $7.60, compared with its previous close of $7.61. In the last trading session, the stock traded between $7.33 and $7.86. It showed a downward intraday trend.
An investment of $100 made 4 years ago in Oculis Holding AG is now worth
$ 68.83
Resulting in a loss of
$ 31.17 (31.17%)
Note: Past profits do not guarantee future returns.
Rating from 5 Analysts
Today's Change
$-0.11 (-1.50%)
Day High
$7.86
Day Low
$7.33
Day Open
$7.60
Prev Close
$7.61
Volume
2,52,075
1W Return
3.12%
1M Return
-4.93%
3M Return
-41.07%
6M Return
-77.04%
1Y Return
-61.36%
Market Cap ($ Mn)
462
PE Ratio
-
PB Ratio
3.04
PEG Ratio
-
ROE
-83.61%
ROCE
-69.57%
EPS (TTM)
$-0.33
1 Week
3.12%
1 Month
-4.93%
3 Months
-41.07%
6 Months
-77.04%
9 Months
-73.77%
Oculis Holding AG to host R&D Day on December 8, 2026
Oculis Holding AG scheduled an R&D Day for December 8, 2026, at St. Regis New York. Event highlights late-stage pipeline including Licaminlimab and Privosegtor. Topline results for Licaminlimab's PREDICT-1 trial expected around year-end. Privosegtor IND clearance for MS relapse indication anticipated this quarter. Two new hires with neurology backgrounds introduced: Prof. Björn Tackenberg and Aaron Tansy.
3 days agoOculis Holding AG Q3FY26 Results: Nine-month net loss narrows 24% to CHF 57.1 million
Net loss for 9M FY26 narrowed 24% YoY to CHF 57.1 million ($71.7 million). Cash and short-term investments stood at CHF 210.3 million ($252.0 million) as of Sept 30, 2026. R&D expenses rose to CHF 15.1 million ($18.5 million) in Q3 FY26 from CHF 14.1 million in Q3 FY25. PREDICT-1 trial randomization complete; topline results expected around year-end 2026. Appointed Prof. Björn Tackenberg as CSO and Aaron Tansy as VP, Neurology Development.
9 days agoOculis appoints Björn Tackenberg as CSO to drive neurology strategy
Björn Tackenberg appointed as Chief Scientific Officer to lead global scientific strategy. Aaron Tansy named Vice President, Development Franchise Head, Neurology. Focus shifts to advancing Privosegtor in optic neuritis and expanding into multiple sclerosis. New leadership combines Roche and academic clinical trial expertise to accelerate development.
10 days agoOculis to feature Privosegtor neuroprotection data at APOIS and CNS summits
Oculis Holding AG will present Privosegtor data at APOIS Congress and CNS Summit. Phase 2 ACUITY trial showed improved visual function and retinal preservation. Privosegtor holds FDA Breakthrough Therapy and EMA PRIME designations. IND clearance for acute multiple sclerosis relapses anticipated in Q4 2026.
14 days agoHC Wainwright reiterates Buy on Oculis Holding, keeps $39 target
HC Wainwright & Co. reiterates Buy rating on Oculis Holding. Analyst Yi Chen maintains $39 price target. Rating reaffirms positive outlook on the stock.
20 days agoOculis to present Privosegtor biomarker data at ACTRIMS meeting
Oculis Holding AG will present Phase 2 ACUITY trial biomarker data at the 10th Joint ACTRIMS-ECTRIMS Meeting. The presentation evaluates plasma NfL and GFAP levels as biomarkers of neuroaxonal injury in optic neuritis patients. Privosegtor holds Breakthrough Therapy designation from the FDA and PRIME designation from the EMA. Oculis plans to file an IND for Privosegtor in acute MS relapses and hosts an R&D Day on December 8, 2026.
24 days ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 4 years ago in Oculis Holding AG is now worth
$ 68.83
Resulting in a loss of
$ 31.17 (31.17%)
Note: Past profits do not guarantee future returns.
